Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Does HE4 have a role as biomarker in the recurrence of ovarian cancer?

Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P, Muzii L, Scaletta G, Benedetti-Panici P, Angioli R.

Tumour Biol. 2012 Dec;33(6):2117-23. doi: 10.1007/s13277-012-0471-7. Epub 2012 Aug 9.

PMID:
22875782
2.

Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.

Shen Y, Li L.

Tumour Biol. 2016 Nov;37(11):14765-14772. Epub 2016 Sep 15.

PMID:
27629144
3.

Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer.

Innao P, Pothisuwan M, Pengsa P.

Asian Pac J Cancer Prev. 2016;17(9):4483-4486.

4.

The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.

Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, Aloisi A, Luvero D, CafĂ  EV, Dugo N, Angelucci M, Benedetti-Panici P.

Tumour Biol. 2013 Feb;34(1):571-6. doi: 10.1007/s13277-012-0583-0. Epub 2012 Nov 20.

PMID:
23179397
5.

[Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].

Wang MJ, Qi J, Wang H, Li XX, Wei BJ, Fu C, Gao J, Han BB.

Zhonghua Zhong Liu Za Zhi. 2011 Jul;33(7):540-3. Chinese.

PMID:
22093635
6.

HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.

Richards A, Herbst U, Manalang J, Pather S, Saidi S, Tejada-Berges T, Tan K, Williams P, Carter J.

Aust N Z J Obstet Gynaecol. 2015 Oct;55(5):493-7. doi: 10.1111/ajo.12363. Epub 2015 Jul 14.

PMID:
26172511
7.

Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to Improve Characterization of Large Ovarian Masses.

Manganaro L, Anastasi E, Porpora MG, Vinci V, Saldari M, Bernardo S, Ballesio L, Sollazzo P, Pecorella I, Recchia N, Stracci F, Panici PB, Angeloni A, Catalano C, Scialpi M.

Anticancer Res. 2015 Nov;35(11):6341-51.

PMID:
26504074
8.

CA125 and HE4 levels in a Czech female population diagnosed with endometrial cancer in preoperative management.

Presl J, Novotny Z, Topolcan O, Vlasak P, Kucera R, Fuchsova R, Vrzalova J, Betincova L, Svobodova S.

Anticancer Res. 2014 Jan;34(1):327-31.

PMID:
24403483
9.

The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program.

Angioli R, Capriglione S, Scaletta G, Aloisi A, Miranda A, De Cicco Nardone C, Terranova C, Plotti F.

Tumour Biol. 2016 Apr;37(4):4973-8. doi: 10.1007/s13277-015-4324-z. Epub 2015 Nov 3.

PMID:
26531723
10.

Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.

Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM.

Diagn Pathol. 2013 Jan 23;8:11. doi: 10.1186/1746-1596-8-11.

11.

Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.

Brennan DJ, Hackethal A, Mann KP, Mutz-Dehbalaie I, Fiegl H, Marth C, Obermair A.

BMC Cancer. 2015 Feb 6;15:33. doi: 10.1186/s12885-015-1028-0.

12.

[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].

Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H.

Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6. Chinese.

PMID:
19134334
13.

Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.

Steffensen KD, Waldstrøm M, Brandslund I, Jakobsen A.

Int J Gynecol Cancer. 2011 Aug;21(6):1040-7. doi: 10.1097/IGC.0b013e31821e052e.

PMID:
21738039
14.

HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.

Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN.

Asian Pac J Cancer Prev. 2010;11(1):111-6.

15.

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Nassir M, Guan J, Luketina H, Siepmann T, Rohr I, Richter R, Castillo-Tong DC, Zeillinger R, Vergote I, Van Nieuwenhuysen E, Concin N, Marth C, Hall C, Mahner S, Woelber L, Sehouli J, Braicu EI.

Tumour Biol. 2016 Mar;37(3):3009-16. doi: 10.1007/s13277-015-4031-9. Epub 2015 Sep 29.

PMID:
26419591
16.

CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.

Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC Jr, Liu J.

Int J Gynecol Cancer. 2013 Jun;23(5):815-22. doi: 10.1097/IGC.0b013e31828f7a24.

17.

The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.

Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, Atanackovic J.

Int J Gynecol Cancer. 2012 Feb;22(2):238-44. doi: 10.1097/IGC.0b013e318234f852.

PMID:
22214964
18.

CA125 and HE4: Measurement Tools for Ovarian Cancer.

Zhao T, Hu W.

Gynecol Obstet Invest. 2016;81(5):430-5. doi: 10.1159/000442288. Epub 2016 Apr 29.

PMID:
27160726
19.

HE4 combined with CA125: favorable screening tool for ovarian cancer.

Ghasemi N, Ghobadzadeh S, Zahraei M, Mohammadpour H, Bahrami S, Ganje MB, Rajabi S.

Med Oncol. 2014 Jan;31(1):808. doi: 10.1007/s12032-013-0808-0. Epub 2013 Dec 10.

PMID:
24323399
20.

Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.

Chen X, Zhou H, Chen R, He J, Wang Y, Huang L, Sun L, Duan C, Luo X, Yan H.

Clin Chim Acta. 2015 Feb 2;440:57-63. doi: 10.1016/j.cca.2014.11.013. Epub 2014 Nov 15.

PMID:
25447698

Supplemental Content

Support Center